Reuters logo
BRIEF-Ipsen receives validation from European Medicines Agency for application of new indication for Cabometyx
September 11, 2017 / 7:00 AM / 13 days ago

BRIEF-Ipsen receives validation from European Medicines Agency for application of new indication for Cabometyx

Sept 11 (Reuters) - IPSEN SA:

* ANNOUNCED ON FRIDAY, IPSEN RECEIVES VALIDATION FROM EUROPEAN MEDICINES AGENCY FOR THE APPLICATION OF A NEW INDICATION FOR CABOMETYX (CABOZANTINIB) FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN ADULTS

* FILING IN FIRST LINE ARCC IS BASED ON THE CABOSUN RESULTS, A PHASE II TRIAL DEMONSTRATING THAT CABOMETYX PROLONGS PROGRESSION-FREE SURVIVAL (PFS) IN TREATMENT-NAIVE PATIENTS WITH INTERMEDIATE- OR POOR-RISK ADVANCED RCC COMPARED TO SUNITINIB

Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below